-+ 0.00%
-+ 0.00%
-+ 0.00%

Structure Therapeutics presents Phase 2b ACCESS obesity trial data for aleniglipron at ADA 2026

PUBT·04/27/2026 20:07:23
Listen to the news
Structure Therapeutics presents Phase 2b ACCESS obesity trial data for aleniglipron at ADA 2026
  • Structure Therapeutics scheduled new Phase 2b ACCESS trial results for oral obesity drug candidate aleniglipron for presentation at American Diabetes Association 86th Scientific Sessions on June 5, 2026.
  • Planned presentation highlights meaningful weight reduction in people with obesity or overweight, supporting continued clinical development of an oral small-molecule GLP-1 option.
  • Separate Phase 2 ACCESS II data on safety, tolerability, and efficacy at higher doses will be presented on June 8, 2026.
  • Late-breaking posters on June 7, 2026 will outline work to improve gastrointestinal tolerability with a lower starting dose, alongside preclinical combination findings pairing aleniglipron with amylin candidate ACCG-2671 that showed additional weight loss versus single-agent treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604271605PRIMZONEFULLFEED9707686) on April 27, 2026, and is solely responsible for the information contained therein.